| pubmed-article:3556121 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C0221102 | lld:lifeskim |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C0521378 | lld:lifeskim |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C0007559 | lld:lifeskim |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C1516634 | lld:lifeskim |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
| pubmed-article:3556121 | lifeskim:mentions | umls-concept:C1517004 | lld:lifeskim |
| pubmed-article:3556121 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:3556121 | pubmed:dateCreated | 1987-7-17 | lld:pubmed |
| pubmed-article:3556121 | pubmed:abstractText | During a 3-h perfusion of five isolated rabbit liver preparations, 1.4% of 10 mg of ceftazidime added to the circulating blood was eliminated in the bile and 0.9% was metabolized or inactivated in the liver. Five normal subjects were given 2 g of ceftazidime intravenously; antibiotic concentration in the aspirated duodenal fluid rose progressively during the 4 h of the investigational period to a maximal mean level of 21.3 +/- s.e.m. 9.2 micrograms/ml and 0.05% of the dose given was recovered during this period. The same dose was given to 12 cholecystectomized patients fitted with a Kehr drain. An average peak value of 36.3 +/- 4.0 micrograms/ml was reached in the collected bile during the second hour after drug administration. The 12-h biliary recovery was 0.21% of the dose given. Ceftazidime concentrations in choledochal and gallbladder bile sampled peroperatively in 10 patients 1 h after intravenous administration of 2 g of ceftazidime were 78.3 +/- 12.0 and 17.9 +/- 7.5 micrograms/ml respectively. These data compare favourably with the results of the authors' studies on the biliary elimination of 15 other beta-lactams and are consistent with a possible beneficial effect of ceftazidime in the treatment of biliary tract infections. | lld:pubmed |
| pubmed-article:3556121 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3556121 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3556121 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3556121 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3556121 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3556121 | pubmed:issn | 0378-6501 | lld:pubmed |
| pubmed-article:3556121 | pubmed:author | pubmed-author:ArnaudJ PJP | lld:pubmed |
| pubmed-article:3556121 | pubmed:author | pubmed-author:MonteilHH | lld:pubmed |
| pubmed-article:3556121 | pubmed:author | pubmed-author:BrogardJ MJM | lld:pubmed |
| pubmed-article:3556121 | pubmed:author | pubmed-author:BlickleJ FJF | lld:pubmed |
| pubmed-article:3556121 | pubmed:author | pubmed-author:JehlFF | lld:pubmed |
| pubmed-article:3556121 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3556121 | pubmed:volume | 13 | lld:pubmed |
| pubmed-article:3556121 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3556121 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3556121 | pubmed:pagination | 105-14 | lld:pubmed |
| pubmed-article:3556121 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:meshHeading | pubmed-meshheading:3556121-... | lld:pubmed |
| pubmed-article:3556121 | pubmed:year | 1987 | lld:pubmed |
| pubmed-article:3556121 | pubmed:articleTitle | Ceftazidime: experimental and clinical evaluation of biliary elimination. | lld:pubmed |
| pubmed-article:3556121 | pubmed:publicationType | Journal Article | lld:pubmed |
